Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.
Tineke W H MeijerMonika G Looijen-SalamonJasper LokMichel van den HeuvelBastiaan TopsJohannes H A M KaandersPaul N SpanJohan BussinkPublished in: Thoracic cancer (2019)
NSCLC is a heterogeneous disease, with differences in mutational status and metabolism-related marker expression between adeno- and squamous cell NSCLCs, and also within adenocarcinoma subtypes. GLUT1 and SLC1A5 expression correlate with aggressive tumor behavior in adenocarcinomas but not in squamous cell NSCLCs. Therefore, these markers could steer treatment modification for subgroups of adenocarcinoma patients. TP53, EGFR and KRAS mutations are associated with expression of glucose and glutamine metabolism-related markers in NSCLC.
Keyphrases
- squamous cell
- small cell lung cancer
- poor prognosis
- advanced non small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- binding protein
- newly diagnosed
- ejection fraction
- long non coding rna
- blood glucose
- epidermal growth factor receptor
- radiation therapy
- peritoneal dialysis
- metabolic syndrome
- combination therapy
- weight loss
- rectal cancer